Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

EGFR mutation testing dropped once funding from pharmaceutical industry discontinued

EGFR mutation testing dropped once funding from pharmaceutical industry discontinued

Seven-year quest to understand how breast cancer cells resist treatment

Seven-year quest to understand how breast cancer cells resist treatment

Researchers find tumors with ALK rearrangements can harbor additional mutations

Researchers find tumors with ALK rearrangements can harbor additional mutations

Review describes current state of lung cancer care

Review describes current state of lung cancer care

Nonfunctional MED12 gene linked to chemotherapy resistance

Nonfunctional MED12 gene linked to chemotherapy resistance

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's

Boehringer Ingelheim files MAA with EMA for afatinib approval

Boehringer Ingelheim files MAA with EMA for afatinib approval

Gefitinib shows promise in Chinese lung cancer patients

Gefitinib shows promise in Chinese lung cancer patients

Addition of sorafenib to chemotherapy does not prolong survival

Addition of sorafenib to chemotherapy does not prolong survival

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Results from Biodesix VeriStrat phase II advanced lung cancer trials

Results from Biodesix VeriStrat phase II advanced lung cancer trials

Progression-free NSCLC survival boosted by dacomitinib

Progression-free NSCLC survival boosted by dacomitinib

Study details canonical Wnt signaling pathway

Study details canonical Wnt signaling pathway

Personalized medicine and the Human Genome Project

Personalized medicine and the Human Genome Project

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

NSCLC patients with EGFR mutations benefit from erlotinib-first regimen

NSCLC patients with EGFR mutations benefit from erlotinib-first regimen